BackZenas BioPharma Overview
Zenas BioPharma, Inc.

Zenas BioPharma Target Price

Analysts' average 12-month price target for Zenas BioPharma is $32.

Get informed when a big investor buys or sells

+ Follow

Share Price

$27.55

Average Target Price

$32.0016.2% upside

1 analysts in the last 4 months

High: $32 | Low: $32

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-14Morgan Stanley$3216.2% upsideOpen
2026-05-14Morgan Stanley$2220.1% downsideOpen
2026-01-06JefferiesRoger Song$4874.2% upsideOpen
2026-01-05Morgan Stanley$1931% downsideOpen
2025-10-28H.C. Wainwright$4459.7% upsideOpen
2025-10-27Morgan StanleySean Laaman$3423.4% upsideOpen
2025-10-27JefferiesRoger Song$5288.7% upsideOpen
2024-10-08JefferiesRoger Song$3527% upsideOpen

Zenas BioPharma (ZBIO) FAQ

Zenas BioPharma posts a target price of $32. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $32 for ZBIO means covering analysts, on average, see the stock 16.2% upside of $27.55 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ZBIO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Zenas BioPharma's other metric pages and overview cover the third.

Judging Zenas BioPharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $32 here, then scan peer and history charts to see if the gap is persistent.